Edward Kliphuis
Partner @ Sofinnova Partners
Amsterdam, The Netherlands
Edward Kliphuis is a Series A investor at Sofinnova Partners in Amsterdam focused on Biotechnology and Artificial Intelligence. Edward Gerrit Roelof Kliphuis is based out of Madrid, Madrid and is the Partner of Sofinnova Partners. Edward previously worked at M Ventures as a Investment Director. Edward Gerrit attended the Leiden University.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries Edward Kliphuis invests in
Stages Edward Kliphuis invests in
Countries Edward Kliphuis invests in
Investment Focus
Industry
- Biotechnology 7 (47%)
- Artificial Intelligence 5 (33%)
- Software 4 (27%)
- Health Care 3 (20%)
- Life Science 3 (20%)
Stage
- Series A 8 (53%)
- Seed 3 (20%)
- Series C 2 (13%)
- Series B 1 (7%)
- Series D 1 (7%)
Country
- United States 5 (33%)
- France 2 (13%)
- United Kingdom 2 (13%)
- Israel 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Excelsior Sciences
|
Excelsior Sciences develops a chemistry and AI platform for discovering and manufacturing small-molecule compounds. It uses a proprietary “smart bloccs” system, which consists of modular, machine-ready chemical building blocks, to convert small-molecule innovation into an iterative, automation-friendly workflow. Through this platform, Excelsiorenables closed-loop cycles of AI-guided synthesis, testing, and optimisation that link early-stage discovery to scalable manufacturing. The company supports projects across pharmaceuticals, materials science, and other sectors that rely on small molecules. Excelsior also maintains an internal pipeline of therapeutic candidates while working with partners to deploy its chemistry platform broadly. | $70M / Series A / Dec 03, 2025 | |
Latent Labs
|
Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today. | $40M / Series A / Feb 13, 2025 | |
Bioptimus
|
Bioptimus is a developer of a universal AI foundation model that connects biology at all sizes, from molecules to cells, tissues, and entire organisms. The company's technology turns multiscale data into actionable representations, allowing clients to spark breakthrough discoveries and expedite biomedical innovation. | $41M / Series A / Jan 14, 2025 | |
|
Bioptimus
|
Bioptimus is a developer of a universal AI foundation model that connects biology at all sizes, from molecules to cells, tissues, and entire organisms. The company's technology turns multiscale data into actionable representations, allowing clients to spark breakthrough discoveries and expedite biomedical innovation. | $35M / Seed / Feb 20, 2024 | |
Betteromics
|
BetterOmics is a SaaS platform that empowers professionals in the life sciences industry with cutting-edge AI and computational techniques. Betteromics is implemented as a Private SaaS within your Virtual Private Cloud (VPC), allowing you to establish connections across all your data sources. Betteromics also enables every role within your team toaccess a centralized, objective source of truth, empowering them with the ability to create accurate and reliable descriptions.Established by experienced executives from Google and GRAIL, the company comprises a group of dedicated professionals driven by a common mission. They bring together expertise from academia, science, and technology sectors. | $20M / Series A / Oct 26, 2023 | |
l'école
|
l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision. | $3M / Seed / Oct 26, 2023 | |
BioCorteX
|
BioCorteX is a pharmaceutical company specializing in enhanced therapeutics to cure neurodegenerative diseases using microorganisms. | $5M / Seed / Mar 28, 2023 | |
Kiro
|
Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology. | $15M / Series A / Mar 28, 2023 | |
Wiliot
|
Wiliot is bringing connectivity and intelligence to everyday products and packaging; things previously disconnect from the Internet of Things. The Wiliot Platform combines cloud services and IoT stickers, computing elements that can power themselves by harvesting radiofrequency energy. This revolutionary mixture of cloud and semiconductortechnology is being used by some of the world’s largest brands, food, and pharmaceutical companies to change how we make, distribute, sell, use and recycle products. | $200M / Series C / Jul 27, 2021 | |
Akili Interactive Labs
|
Akili Interactive Labs their broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity and disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases. | $110M / Series D / May 26, 2021 | |
| See all 15 investments → | |||
Co-Investors
About Sofinnova Partners
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage.The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential topositively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs.It was headquartered in Paris, Ile-de-France in 1972.
Sofinnova Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Tingaud
Venture Partner
|
|||
Cedric Moreau
Partner
|
|||
Dominique Verdier
Operations
|
|||
|
Edward Kliphuis
Partner
|
|||
Jacques Theurillat
Partner, Crossover fund
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Edward Kliphuis invest in?
Edward Kliphuis invests primarily in Biotechnology, Artificial Intelligence and Software startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Edward Kliphuis last invest?
The most recent investment recorded for Edward Kliphuis closed in Dec 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
